Core Viewpoint - Peijia Medical-B (09996) has seen a significant increase in stock price, attributed to the chairman's confidence demonstrated through share buybacks and the recent approval of its TaurusTrio device for market entry [1][2] Group 1: Company Developments - Peijia Medical's stock rose over 6%, with a cumulative increase of over 22% in December [1] - The chairman, Dr. Zhang Yi, plans to invest up to 15 million HKD in purchasing company shares from the open market [1] - The TaurusTrio transcatheter aortic valve system has received approval from the National Medical Products Administration, marking it as the first integrated positioning key transcatheter aortic valve regurgitation intervention device approved in China [1] Group 2: Industry Position - According to CITIC Securities, Peijia Medical holds a leading position in the domestic heart valve intervention market, with positive clinical feedback and increasing market share for its TAVR products since commercialization [2] - The company has a comprehensive product development layout in aortic, mitral, and tricuspid valve treatment areas, which helps solidify its leading position in the heart valve sector [2] - Peijia Medical anticipates the approval and commercialization of three major products by the end of 2025 to 2026, which is expected to drive a rapid recovery in overall performance [2] - The company's neurointerventional business is among the top domestic players, with a promising growth trend expected as the product pipeline continues to expand and commercialization progresses [2]
港股异动 | 沛嘉医疗-B(09996)再涨超6% 董事长增持彰显信心 旗下TaurusTrio近日获批上市